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Introduction 
Noninvasive diagnosis of coronary artery disease (CAD) and risk assessment represents 
major challenge for clinical decision-making in patients with suspected CAD (1). Coronary 
artery calcium (CAC) score evaluation demonstrated to have a significant role in 
appropriate management of patients with suspected CAD (2). In particular, CAC scoring 
resulted as a powerful tool in risk-stratifying asymptomatic patients at intermediate risk of 
CAD (3). It has been also demonstrated that not only the presence but also the extent of 
coronary calcification significantly improve the prediction of cardiovascular events in 
addition to traditional cardiovascular risk factors (4). Myocardial perfusion imaging (MPI) 
with positron emission tomography (PET)/computed tomography (CT) allows absolute 
quantification of myocardial blood flow (MBF) and coronary flow reserve (CFR) with a 
feasible possibility to perform CAC quantification as a part of the same examination (5). 
Different published data have demonstrated that the presence of abnormal CFR by PET 
using different tracers, reflecting both the presence of epicardial coronary artery stenosis 
and microvascular dysfunction, was significantly associated with a higher cardiac event rate 
in patients with suspected and known CAD (6,7). Thus, recently some studies evaluated the 
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combined role of structural and functional information obtained by PET/CT in the 
evaluation of patients with suspected or known CAD (8,9). In particular, a significant 
inverse relationship between extent of CAC and CFR by rubidium-82 (82Rb) PET/CT has 
been observed in patients with suspected CAD (9). However, few data are available 
combining measures of structural abnormalities and coronary vasodilator function by 82Rb 
PET/CT in predicting adverse cardiac events. Thus, aim of this study was to evaluate the 
long-term prognostic value of CAC score and MBF by hybrid 82Rb PET/CT imaging in a 
cohort of patients with low-intermediate risk of CAD. 
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 Methods 
Patient population 
The study population comprised 295 subjects referred to CAC scoring and MBF 
measurements by PET/CT for atypical cardiac chest pain. For each patient the presence of 
coronary risk factors was noted. Hypertension was defined as a blood pressure ≥140/90 
mmHg or the use of anti-hypertensive medication (10). Hypercholesterolemia was defined 
as total cholesterol level >6.2 mmol/L or treatment with cholesterol lowering medication. 
Patients were classified as having diabetes if they were receiving treatment with oral 
hypoglycemic drugs or insulin. A positive family history of CAD was defined by the 
presence of disease in first-degree relatives younger than 55 years in men or 65 years in 
women. Exclusion criteria were documented history of CAD defined as previous 
percutaneous coronary intervention, coronary artery bypass graft surgery, or myocardial 
infarction. Patients with uncontrolled atrial fibrillation, pacemaker, or prosthetic valve were 
also excluded. 
Pet imaging 
 As a routine preparation for 82Rb cardiac PET/CT, patients were asked to discontinue 
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taking nitrates for 6 hours, calcium channel blockers and caffeine-containing beverages for 
24 hours, and b-blockers for 48 hours before their appointment. Scans were acquired using a 
Biograph mCT 64-slice scanner (Siemens Healthcare). Rest and stress cardiac PET/CT 
images were acquired as follows: scout CT to check the patient position and low-dose CT 
(0.4 mSv; 120 kVp; effective tube current, 26 mA [11-mAs quality reference]; 3.3 seconds) 
were performed for attenuation correction, during normal breathing before and after PET 
acquisitions. For both rest and stress images 1110 MBq of 82Rb were injected intravenously 
and a 6-minute list-mode PET study was acquired. Pharmacologic stress was then 
administered using adenosine (140 µg·kg-1·min-1 for 4.5 minutes). Both rest and stress 
dynamic images were reconstructed into 26 time frames (12 x 5 seconds, 6 x 10 seconds, 4 
x 20 seconds, and 4 x 40 seconds; total, 6 minutes) using the vendor standard ordered 
subsets expectation maximization 3D reconstruction (2 iterations, 24 subsets) with 6.5-mm 
gaussian post-processing filter. Regional myocardial perfusion was visually assessed, using 
standardized segmentation of 17 myocardial regions (11). Each myocardial segment was 
scored from normal (score = 0) to absent perfusion (score = 4). The summed stress score 
was obtained by adding the scores of the 17 segments of the stress images. A similar 
procedure was applied to the resting images to calculate the summed rest score and summed 
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difference score was the difference between the stress and rest scores. Myocardial perfusion 
was considered abnormal when summed stress score was ≥3. Subjects with summed 
difference score ≥2 were defined as having stress-induced myocardial ischemia (2-6 mild 
ischemia and >6 moderate-severe ischemia). Absolute MBF (in mL·min-1·g-1) was 
computed from the dynamic rest and stress imaging series with commercially available 
software (Siemens Syngo Dynamic PET) (12). CFR was defined as the ratio of hyperemic 
to baseline MBF and was considered reduced when <2 (13). 
CT imaging 
 All patients underwent a CT scan for CAC scoring. Those with heart rate >75 bpm received 
prior intravenous betablockers (5-10 mg atenolol). A standard scanning protocol was 
applied, with 18 mm section collimation (30 9 0.6 mm), 0.24 ms gantry rotation time, 120 
kVp tube voltage, and 60 Q ref mAs tube current. CAC scoring was obtained during a single 
breath hold and coronary calcification was defined as a plaque with an area of 1.03 mm2 and 
a density ≥130 HU. The CAC score was calculated according to the method described by 
Agatston (14). Experienced nuclear medicine physicians analyzed the CT, blinded to the 
PET results (Siemens, Syngo Multimodality Workplace). CAC scores were calculated 
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separately for the LAD, LCx, and RCA coronary arteries and summed to provide a total 
CAC score. CAC score was also categorized into 3 groups (0,1-399 and ≥400). 
Follow-up data 
Patient follow-up was prospectively obtained by use of a questionnaire that was assessed by 
a phone call to all patients and general practitioners or cardiologists and by review of 
hospital or physicians’ records by individuals blinded to the patient’s test results. The 
outcome was a composite end point of cardiac death, nonfatal myocardial infarction, or 
unstable angina requiring coronary revascularization whichever occurred first. The cause of 
death was confirmed by review of death certificate, hospital chart, or physician’s records. 
Death was considered to be of cardiac origin if the primary cause was defined as acute 
myocardial infarction, congestive heart failure, valvular heart disease, sudden cardiac death, 
cardiac interventional/surgical procedure related. Myocardial infarction was defined when 
>2 of the following 3 criteria were met: chest pain or equivalent symptom complex, positive 
cardiac biomarkers, or typical electrocardiographic changes (15). The date of the last 
examination or consultation was used to determine the length of follow-up. 
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Statistical analysis 
Continuous data are expressed as mean ± standard deviation and categorical data as 
percentage. Comparison between groups was performed with unpaired t test and Chi-square 
test as appropriate. A P value <.05 was considered statistically significant. The ln(CAC+1) 
score transformation was used to adjust for the rightward skew of the data and to reduce 
heteroscedasticity. Survival analysis was performed by univariable and multivariable Cox 
proportional hazard regression analysis. Only variables showing a P value <.05 at 
univariable analysis were considered for multivariable analysis. Event-free survival curves 
were obtained by the Kaplan-Meier method and compared with the log-rank test. The 
incremental prognostic value of clinical data and imaging findings was assessed considering 
variables in hierarchical order. To address the incremental prognostic value of CAC score, 
we added CAC score to a model including only clinical variables (model 1) to obtain an 
adjusted hazard ratio for CAC (model 2). Moreover, to evaluate incremental prognostic 
value of CFR, we added CFR to a model 2, including clinical data and CAC score. All the 
analyses were performed using STATA version 14.0 for Windows (StataCorp LP, College 
Station, TX).    
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Results 
 Patient Characteristics and Outcome 
Of the 295 patients enrolled, follow-up data were not available in 26 patients (8%). The 
median follow-up was 48±18 months. During follow-up, 17 events occurred (6% 
cumulative event rate). The events were cardiac death in 3 patients, nonfatal myocardial 
infarction in 3 and unstable angina requiring revascularizations in 11. Clinical 
characteristics of patients with and without events were reported in Table 1. Patients who 
experienced event were older and showed higher prevalence of hypertension and 
dyslipidemia and a higher BMI value as compared to patients without event. Of the overall 
patients, normal myocardial perfusion was observed in 238 (88%) patients, while 31 (12%) 
patients showed stress-induced mild ischemia. In particular, the prevalence of abnormal 
MPI was significantly higher in patients with events as compared to those without (41% vs 
9%, respectively P <.001). Coronary artery calcium and vascular function of the overall 
patients were reported in Table 2. As showed patients who experienced event showed a 
higher ln(CAC + 1) and a lower CFR values as compared to patients without event, while 
no differences has been observed in baseline and hyperemic MBF between the two groups. 
Moreover, patients with event had a lower prevalence of CAC score 0 and a higher 
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prevalence of CAC ≥400 as compared to patients without events. On the contrary, the 
prevalence of CAC score 1-399 was not significantly different between the two groups. 
Event rate in both CAC score and CFR categories was illustrated in Table 3. As shown, 
event rate significantly increased with increasing of CAC score categories (P for trend = 
.000) and it was higher in patients with reduced CFR (P = .001).   
Predictors of events  
 Univariable and multivariable Cox regression analyses were reported in Table 4. As shown, 
age (P = .01), diabetes (P = .04), hypertension (P = .03), dyslipidemia (P = .02), CAC score 
(P = .002) and CFR (P = .000) were predictors of events. Moreover, at multivariable 
analysis CAC score ≥400 (P = .007) and CFR (P = .03) were independent predictors of 
events.  The event-free survival curves according to CAC score categories and CFR were 
reported in Figure 1 and 2. As illustrated, event-free survival decreased with worsening of 
CAC score category (P <.001) and in patients with reduced CFR (P <.005). The results of 
incremental analysis were reported in Figure 3. CAC score added prognostic information to 
a model including in hierarchical order clinical variables, increasing the global chi-square 
from 21.65 to 28.78 (P = .005). Moreover, the addition of CFR to a model including clinical 
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data and CAC score further significantly increased global chi-square from 28.78 to 34.76 (P 
= .002).  
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Discussion 
 From this study it emerged that both the extent of coronary calcification and the presence of 
coronary vascular dysfunction by 82Rb cardiac PET/CT are associated with increased risk of 
adverse cardiac events, even after adjustment for cardiovascular risk factors. In particular, 
the presence of CAC score ≥400 and CFR resulted as independent predictors of events.  
The presence of CAC score is indicative of the overall coronary atherosclerotic burden and 
is a strong predictor of cardiac events, as investigated in several studies (16,17). In 
particular, it has been demonstrated a very low rate of cardiovascular events among patients 
with CAC score of zero (16) while event rate increase incrementally according to CAC 
score among those with abnormal CAC scans (17). In a large cohort of asymptomatic 
patients, Budoff et al. (17) have demonstrated that the increase of plaque burden is 
associated with increasing risk, supporting evidence that there is a relationship between the 
extent of CAC and all-cause mortality. Moreover, when CAC score was added to risk 
factors provided incremental information for predicting outcomes (18). In a large study 
population with suspected CAD, CAC score has demonstrated to provide the highest 
improvement in the prediction of event over the other cardiovascular risk markers, 
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suggesting the use of CAC as a powerful tool for improving cardiovascular risk prediction 
in individuals classified as intermediate risk (18). PET imaging is a noninvasive procedure 
with the potential for absolute quantification of MBF and CFR as markers of coronary 
vascular function, and several studies have demonstrated the prognostic role of PET-derived 
flow reserve in subjects with and without known CAD (7,19). In particular, inclusion of 
CFR in the risk prediction models provided incremental risk stratification beyond clinical 
and perfusion variables and resulted in a significant incremental risk reclassification of 
patients with known or suspected CAD (19). Moreover, the incremental prognostic value of 
CFR over standard relative MPI in predicting outcomes it has been widely outlined (20). A 
combined evaluation of CAC score and coronary vascular function could significantly 
change clinical management of patient with suspected CAD. Dikic et al. (21) in a cohort of 
asymptomatic diabetic patients, demonstrated that both CAC score and coronary flow 
velocity reserve obtained by MSCT and by transthoracic Doppler echocardiography 
assessments respectively, provide independent and complementary prognostic information. 
A combined use of the two parameters improved the risk stratification ability and identified 
patients at higher risk who could benefit from more aggressive treatment (21). A principal 
advantage of hybrid PET/CT is its potential ability to evaluate both the coronary 
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atherosclerotic burden as assessed by CAC score and coronary vascular function as CFR in 
a same examination. However, only few data are available about the use of combined 
measure of structural abnormalities and coronary vasodilator function by 82Rb PET/CT in 
predicting adverse cardiac events. In a previous study, Naya et al. (22) in a cohort of 901 
symptomatic patients with suspected CAD, undergoing 82Rb PET/CT, and followed for a 
median of 1.53 years, demonstrated that both the extent of coronary calcium deposits and 
the presence of coronary vascular dysfunction are associated with increased risk of adverse 
cardiac events. However, after adjustment for clinical risk only coronary vascular 
dysfunction improved risk assessment, confirming that total burden of coronary calcium 
deposits was only modestly associated with impaired vascular function. They concluded that 
direct measures of coronary vasodilator function might be more powerful marker of cardiac 
risk than simply the total burden of calcified atherosclerosis. To the best of our knowledge 
this is the first study assessing the long-term (48±18 months) prognostic value of combining 
measures of structural abnormalities and coronary vasodilator function by 82Rb PET/CT to 
predict adverse cardiac events in subjects with suspected CAD. Recently, the presence of 
negative correlation between the extent of coronary calcification and coronary vascular 
function has been demonstrated in a similar cohort of patients (3). In particular, CAC score 
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≥400 resulted associated with coronary vascular dysfunction and reduced CFR reflecting the 
effects of coexisting coronary risk factors on endothelial and microvascular function (3). 
Interestingly in the present study both CAC score ≥400 and CFR were significant predictors 
of cardiac events. Moreover, the results of our study showed that event-free survival 
decreased with worsening of CAC score categories and it was worse in patients with 
reduced CFR. Finally, we evaluated incremental prognostic value of CFR in predicting 
cardiac adverse events. In our study CAC score added prognostic information to a model 
including in hierarchical order clinical variables. The addition of CFR to a model including 
clinical data and CAC score further significantly increased the prognostic power of the 
model. Our work has important clinical implications, suggesting that a combined evaluation 
of functional and structural abnormalities by hybrid 82Rb PET/CT imaging might be a 
potential screening tool to identify patients with low-intermediate risk of CAD at higher risk 
of cardiac event during at long-term follow-up. 
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 Conclusions 
 In patients with suspected CAD both the extent of coronary calcification and the presence 
of coronary vascular dysfunction are associated with increased risk of adverse cardiac 
events, even after adjustment for cardiovascular risk factors. CAC score≥400 and CFR 
resulted both as independent predictors of events. However, CFR provides incremental 
prognostic information over established CAD risk factors and CAC score for predicting 
cardiac adverse events. Combined evaluation of functional and structural abnormalities 
might allow risk stratification in patients with low-intermediate risk of CAD. 
 
 
 
18 
 
References 
1. Berman DS, Hachamovitch R, Shaw LJ, Friedman JD, Hayes SW, Thomson LE, 
Fieno DS, Germano G, Wong ND, Kang X, Rozanski A. Roles of nuclear 
cardiology, cardiac  computed tomography, and cardiac magnetic resonance: 
Noninvasive risk stratification and a conceptual framework for the selection of 
noninvasive imaging tests in patients with known or suspected coronary artery 
disease. J Nucl Med. 2006 Jul;47(7):1107-18 Review. PubMed PMID: 16818945. 
2. Lee H, Yoon YE, Park JB, Kim HL, Park HE, Lee SP, Kim HK, Choi SY, Kim YJ, 
Cho GY, Zo JH, Sohn DW. The Incremental Prognostic Value of Cardiac Computed 
Tomography in Comparison with Single-Photon Emission Computed Tomography 
in Patients with Suspected Coronary Artery Disease. PLoS One. 2016 Aug 
3;11(8):e0160188. doi: 10.1371/journal.pone.0160188. PubMed PMID: 27486804; 
PubMed Central PMCID: PMC4972322. 
3. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, American 
College of Cardiology Foundation, American Heart Association, et al. ACCF/AHA 
guideline for assessment of cardiovascular risk in asymptomatic adults: a report of 
19 
 
the American College of Cardiology Foundation/American Heart Association Task 
Force on Practice Guidelines. J Am CollCardiol. 2010;2010:e50-103. 
4. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, 
Greenland P (2010) Coronary artery calcium score and risk classification for 
coronary heart disease prediction. JAMA 303:1610-1616. 
5. Bybee KA, Lee J, Markiewicz R, Longmore R, McGhie AI, O'Keefe JH, Hsu BL, 
Kennedy K, Thompson RC, Bateman TM. Diagnostic and clinical benefit of 
combined coronary calcium and perfusion assessment in patients undergoing 
PET/CT myocardial perfusion stress imaging. J Nucl Cardiol. 2010 Apr;17(2):188-
96. doi:  10.1007/s12350-009-9159-9. PubMed PMID: 20012515. 
6. Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, Dorbala S, 
Blankstein R, Di Carli MF. Global coronary flow reserve is associated with adverse 
cardiovascular events independently of luminal angiographic severity and  modifies 
the effect of early revascularization. Circulation. 2015 Jan 6;131(1):19-27. doi: 
10.1161/CIRCULATIONAHA.114.011939. PubMed PMID: 25400060; PubMed 
Central PMCID: PMC4286486. 
20 
 
7. Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, Burkhard N, 
Wyss CA, Kaufmann PA. Long-term prognostic value of 13N-ammonia myocardial 
perfusion positron emission tomography added value of coronary flow reserve. J Am 
Coll Cardiol. 2009 Jul 7;54(2):150-6. doi: 10.1016/j.jacc.2009.02.069. PubMed 
PMID: 19573732. 
8. Danad I, Raijmakers PG, Appelman YE, Harms HJ, de Haan S, Marques KM, van 
Kuijk C, Allaart CP, Hoekstra OS, Lammertsma AA, Lubberink M, van Rossum 
AC, Knaapen P. Quantitative relationship between coronary artery calcium score 
and hyperemic myocardial blood flow as assessed by hybrid 15O-water PET/CT 
imaging in patients evaluated for coronary artery disease. J Nucl Cardiol. 2012 
Apr;19(2):256-64. doi: 10.1007/s12350-011-9476-7. PubMed PMID: 22076826; 
PubMed Central PMCID: PMC3313028. 
9. Assante R, Zampella E, Arumugam P, Acampa W, Imbriaco M, Tout D, Petretta M, 
Tonge C, Cuocolo A. Quantitative relationship between coronary artery calcium and 
myocardial blood flow by hybrid rubidium-82 PET/CT imaging in patients with  
21 
 
suspected coronary artery disease. J Nucl Cardiol. 2016 Jan 15. [Epub ahead of   
print] PubMed PMID: 26780529. 
10. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, et al. Treatment 
of hypertension in the prevention and management of ischemic heart disease: A 
scientific statement from the American Heart Association Council for High Blood 
Pressure Research and the Councils on Clinical Cardiology and Epidemiology and 
Prevention. Circulation 2007;115:2761-88. 
11. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. 
Standardized myocardial segmentation and nomenclature for tomographic imaging 
of the heart. A statement for healthcare professionals from the Cardiac Imaging 
Committee of the Council on Clinical Cardiology of the American Heart 
Association. Circulation 2002;105:539-42. 
12. Klein R, Renaud JM, Ziadi MC, Thorn SL, Adler A, Beanlands RS, et al. Intra- and 
inter-operator repeatability of myocardial blood flow and myocardial flow reserve 
measurements using rubidium-82 pet and a highly automated analysis program. J 
NuclCardiol 2010;17:600-16. 
22 
 
13. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 
2007;356:830-40. 
14. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, ViamonteMJr, Detrano R. 
Quantification of coronary artery calcium using ultrafast computed tomography. J 
Am CollCardiol 1990;15:827- 32. 
15. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, WhiteHD. Joint 
ESC/ACCF/AHA/WHF task force for the universal definition of myocardial 
infarction. Third universal definition of myocardial infarction. Circulation. 
2012;126:2020-35. 
16. Budoff MJ, McClelland RL, Nasir K, Greenland P, Kronmal RA, Kondos GT, Shea 
S, Lima JA, Blumenthal RS. Cardiovascular events with absent or minimal coronary 
calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2009 
Oct;158(4):554-61. doi: 10.1016/j.ahj.2009.08.007. PubMed PMID: 19781414; 
PubMed Central PMCID: PMC2766514. 
17. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, 
Callister TQ, Raggi P, Berman DS. Long-term prognosis associated with coronary 
23 
 
calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 
2007 May 8;49(18):1860-70. PubMed PMID: 17481445. 
18. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, 
Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for 
improvement in cardiovascular risk assessment in intermediate-risk individuals. 
JAMA. 2012 Aug 22;308(8):788-95. doi: 10.1001/jama.2012.9624. PubMed PMID: 
22910756; PubMed Central PMCID: PMC4141475.  
19.  Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, Blankstein R, 
Dorbala S, Sitek A, Pencina MJ, Di Carli MF. Improved cardiac risk assessment 
with noninvasive measures of coronary flow reserve. Circulation. 2011 Nov 
15;124(20):2215-24. doi: 10.1161/CIRCULATIONAHA.111.050427. PubMed 
PMID: 22007073; PubMed Central PMCID: PMC3495106. 
20. Ziadi MC, Dekemp RA, Williams KA, Guo A, Chow BJ, Renaud JM, Ruddy TD, 
Sarveswaran N, Tee RE, Beanlands RS. Impaired myocardial flow reserve on 
rubidium-82 positron emission tomography imaging predicts adverse outcomes in 
24 
 
patients assessed for myocardial ischemia. J Am Coll Cardiol. 2011 Aug 
9;58(7):740-8. doi: 10.1016/j.jacc.2011.01.065. PubMed PMID: 21816311. 
21. Dikic M, Tesic M, Markovic Z, Giga V, Djordjevic-Dikic A, Stepanovic J, Beleslin 
B, Jovanovic I, Mladenovic A, Seferovic J, Ostojic M, Arandjelovic A. Prognostic 
value of calcium score and coronary flow velocity reserve in asymptomatic diabetic 
patients. Cardiovasc Ultrasound. 2015 Sep 4;13:41. doi: 10.1186/s12947-015-0035-
2. PubMed PMID: 26340922; PubMed Central PMCID: PMC4560883. 
22. Naya M, Murthy VL, Foster CR, Gaber M, Klein J, Hainer J, Dorbala S, Blankstein 
R, Di Carli MF. Prognostic interplay of coronary artery calcification  and underlying 
vascular dysfunction in patients with suspected coronary artery disease. J Am Coll 
Cardiol. 2013 May 21;61(20):2098-106. doi: 10.1016/j.jacc.2013.02.029. PubMed 
PMID: 23524053; PubMed Central PMCID: PMC3753576. 
Table 1. Clinical characteristics of patients with and without events 
 
 All 
(n=269) 
Events 
(n=17) 
No events 
(n=252) 
P value 
Age 57 ± 14 64 ± 11 57 ± 14 .037 
Male Gender 138(51%) 10(59%) 128(50%) .521 
BMI 30 ± 6 34 ± 9 30 ± 6 .014 
Diabetes 53(19%) 6(35%) 47(18%) .095 
Hypertension 174(65%) 15(88%) 159(63%) .036 
Dyslipidemia 147(55%) 14(82%) 133(53%) .018 
Smoking history 69(26%) 2(12%) 67(26%) .176 
Family history of CAD 128(47%) 11(65%) 117(46%) .144 
Values are expressed as mean value  standard deviation or as number (percentage) of subjects 
CAD, coronary artery disease; BMI, body mass index 
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Table 2. Coronary artery calcium and vascular function 
 All 
(n=269) 
Events 
(n=17) 
No events 
(n=252) 
P value 
Ln(CAC+1) score 2.43±2.83 5.28±2.23 2.24±2.77 .000 
CAC categories     
0 141(52%) 1 (6%) 140 (55%) .000 
1-399 77(29%) 6 (35%) 71 (28%) .694 
≥400 51(19%) 10 (59%) 41 (16%) .000 
Hyperemic MBF 2.56±0.89 2.25 ±0.93 2.58 ±0.89 .133 
Rest MBF 1.10 ±0.41 1.25 ±0.42 1.09 ±0.40 .137 
CFR 2.47 ±0.75 1.84 ±0.48 2.52 ±0.75 .000 
CFR<2 105(39%) 13 (76%) 92 (36%) .001 
Values are expressed as mean value ± standard deviation or as number (percentage) of subjects. 
CAC, coronary artery calcium; MBF, myocardial blood flow; CFR, coronary flow reserve. 
 
 
 
 
27 
 
Table 3.  Adverse cardiac events according to coronary artery calcium (CAC) score and coronary flow 
reserve (CFR) 
 Patients (n) Events (%) 
CAC score categories   
0 141 0.7% 
1-399.9 77 8% 
≥400 51 20% 
Coronary flow reserve   
CFR>2 164 2% 
CFR<2 105 12% 
CAC, coronary artery calcium; CFR, coronary flow reserve. 
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Table 4.Univariable and multivariable predictors of cardiac events 
 Univariable analysis Multivariable analysis 
 Hazard ratio (CI) P value Hazard ratio (CI) P value 
Age 1.048 (1.008-1.090) .018 0.984 (0.935-1.035) .984 
Male Gender 0.696 (0.265-1.829) .462   
BMI 1.021 (1.010-1.138) .023 1.049 (0.977-1.128) .188 
Diabetes 2.812 (1.036-7.636) .043 0.979 (0.340-2.825) .969 
Hypertension 4.958 (1.132-21.717) .034 2.393 (0.536-10.679) .253 
Dyslipidemia 4.242 (1.219-14.766) .023 2.114 (0.561-7.971) .269 
Smoking history 0.421 (0.096-1.842) .421   
Family history of CAD 1.217 (0.819-5.999) .117   
CAC score 0(reference)  .002  .016 
CAC score 1-399 11.909 (1.433-98.985) .022 7.985 (0.903-70.623) .062 
CAC score ≥400 30.279 (3.873-236.698) .001 21.187 (2.293-195.781) .007 
CFR  0.213 (0.092-0.495) .000 3.738 (1.096-12.750) .035 
BMI, body mass index; CAD, coronary artery disease; CAC, coronary artery calcium; CFR, coronary 
flow reserve. 
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Figure Legends 
Figure 1. Event-free survival curves by Kaplan-Meier analysis according to CAC score categories 
Figure 2. Event-free survival curves by Kaplan-Meier analysis according to CFR categories  
Figure 3. Incremental prognostic value (global Chi-square values on y-axis) of clinical data, CAC 
score and CFR 
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